The Medicines and Healthcare Products Regulatory Agency (MHRA) has approved Bocouture, a botulinum neurotoxin type A treatment, in the UK for treatment of upper facial lines.
Bocouture is distributed by Merz Pharma UK, who claim the product is the only neurotoxin approved in the UK for combined upper facial line treatments, including horizontal frown lines, lateral periorbital lines and glabellar frown lines.
“Merz is a global leader in the aesthetics space and is proud to be able to provide patients and physicians in the UK with the first and only aesthetic neurotoxin approved for combination treatment of upper facial lines,” said managing director of Merz Pharma UK, Stuart Rose.
He continued, “This expanded indication for Bocouture is a result of our on-going investment in research and development and supports our vision to become the most admired, trusted and innovative aesthetics and neurotoxins company worldwide.”
According to Merz, the approval of the treatment is based on the results of a pivotal randomised double-blind, placebo-controlled study consisting of 156 patients from the UK, France and Germany.
The patients received upper facial line treatment with Bocouture, and researchers found that the product was safe and efficient in treating upper facial lines, both combined and separately, with effects lasting for up to four months.